Guardion Health Sciences Exhibiting at Caribbean Eye Meeting
Guardion Health Sciences, an ocular health sciences technology company, will be exhibiting at the Caribbean Eye Meeting in February.
San Diego, CA, February 02, 2018 --(PR.com)-- Guardion Health Sciences, a leader in ocular health technologies and products, will be exhibiting at the Caribbean Eye Meeting, February 2 to 6, 2018.
The Caribbean Eye Meeting is an annual conference that brings together licensed professionals in vision and eye care to discuss topics surrounding the educational needs of ophthalmology, optometry, and allied health in the pursuit of enhancing patient outcomes and benefits and bringing about innovative technologies and methodologies. The conference includes panel discussions, lectures, in-depth question and answer sessions, and presentations of case studies. Hosted by the American College of Eye Surgeons and the American Board of Eye Surgery with support from the Society for Excellence in Eyecare, the Caribbean Eye Meeting enters its 28th annual meeting and will be held at the Ritz-Carlton in Cancun, Mexico.
“Guardion Health Sciences is delighted to be attending the Caribbean Eye meeting for the first time in 2018,” said Gordon Bethwaite, Chief Marketing Officer at Guardion Health Sciences. “This event is renowned for its collegiate atmosphere, access to attendees, excellent speakers and educational content. We’re honored to count Caribbean Eye past president and honorary chair, Dr. Dee Stephenson, as one of our Medical Advisory Board members, and are proud to support the meeting at which Dr. Stephenson has been such a driving force. Dr. David Evans, founder of VectorVision and Guardion board member, is also part of the faculty at this prestigious event, and we look forward to the opportunity of presenting the Guardion portfolio to everyone attending the meeting.”
Guardion will be exhibiting at the meeting, where they will display the CSV-1000 device, the global standard for contrast sensitivity testing, and have samples of Lumega-Z, the only medical food designed to restore and maintain the macular pigment. Guardion will also be showing a video loop of the Mapcat device, the new standard for macular pigment optical density testing.
About Guardion Health Sciences, Inc.
Guardion Health Sciences, Inc. is a specialty health sciences company that develops, formulates and distributes condition-specific medical foods, with an initial medical food product that addresses a depleted macular protective pigment, a known risk factor for age-related macular degeneration (“AMD”), and a significant component of functional vision performance. Guardion Health Sciences, Inc., has also developed a proprietary medical device, the MapcatSF®, which accurately measures the macular pigment density, therefore providing the only two-pronged evidence based protocol for the management of the macular pigment.
About VectorVision®
VectorVision® specializes in the standardization of contrast sensitivity, glare sensitivity, low contrast acuity, and ETDRS acuity vision testing. Its patented standardization system provides the practitioner or researcher the ability to delineate very small changes in visual capability, either as compared to the population or from visit to visit. VectorVision®’s CSV-1000 device is considered the standard of care for clinical trials.
Forward-Looking Statement Disclaimer
With the exception of the historical information contained in this news release, the matters described herein contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements involve unknown risks and uncertainties that may individually or materially impact the matters discussed herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company’s ability to raise sufficient financing to implement its business plan and its ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s most recent Form 10-K filed with the Securities and Exchange Commission (“SEC”), as well as the financial statements included therein and in subsequent Form 10-Q filings. These filings are available at the SEC’s website (www.sec.gov). The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
The Caribbean Eye Meeting is an annual conference that brings together licensed professionals in vision and eye care to discuss topics surrounding the educational needs of ophthalmology, optometry, and allied health in the pursuit of enhancing patient outcomes and benefits and bringing about innovative technologies and methodologies. The conference includes panel discussions, lectures, in-depth question and answer sessions, and presentations of case studies. Hosted by the American College of Eye Surgeons and the American Board of Eye Surgery with support from the Society for Excellence in Eyecare, the Caribbean Eye Meeting enters its 28th annual meeting and will be held at the Ritz-Carlton in Cancun, Mexico.
“Guardion Health Sciences is delighted to be attending the Caribbean Eye meeting for the first time in 2018,” said Gordon Bethwaite, Chief Marketing Officer at Guardion Health Sciences. “This event is renowned for its collegiate atmosphere, access to attendees, excellent speakers and educational content. We’re honored to count Caribbean Eye past president and honorary chair, Dr. Dee Stephenson, as one of our Medical Advisory Board members, and are proud to support the meeting at which Dr. Stephenson has been such a driving force. Dr. David Evans, founder of VectorVision and Guardion board member, is also part of the faculty at this prestigious event, and we look forward to the opportunity of presenting the Guardion portfolio to everyone attending the meeting.”
Guardion will be exhibiting at the meeting, where they will display the CSV-1000 device, the global standard for contrast sensitivity testing, and have samples of Lumega-Z, the only medical food designed to restore and maintain the macular pigment. Guardion will also be showing a video loop of the Mapcat device, the new standard for macular pigment optical density testing.
About Guardion Health Sciences, Inc.
Guardion Health Sciences, Inc. is a specialty health sciences company that develops, formulates and distributes condition-specific medical foods, with an initial medical food product that addresses a depleted macular protective pigment, a known risk factor for age-related macular degeneration (“AMD”), and a significant component of functional vision performance. Guardion Health Sciences, Inc., has also developed a proprietary medical device, the MapcatSF®, which accurately measures the macular pigment density, therefore providing the only two-pronged evidence based protocol for the management of the macular pigment.
About VectorVision®
VectorVision® specializes in the standardization of contrast sensitivity, glare sensitivity, low contrast acuity, and ETDRS acuity vision testing. Its patented standardization system provides the practitioner or researcher the ability to delineate very small changes in visual capability, either as compared to the population or from visit to visit. VectorVision®’s CSV-1000 device is considered the standard of care for clinical trials.
Forward-Looking Statement Disclaimer
With the exception of the historical information contained in this news release, the matters described herein contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements involve unknown risks and uncertainties that may individually or materially impact the matters discussed herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company’s ability to raise sufficient financing to implement its business plan and its ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s most recent Form 10-K filed with the Securities and Exchange Commission (“SEC”), as well as the financial statements included therein and in subsequent Form 10-Q filings. These filings are available at the SEC’s website (www.sec.gov). The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact
Guardion Health Sciences, Inc.
Michael Favish
(858) 605-9055
https://guardionhealth.com/
Michael Favish
(858) 605-9055
https://guardionhealth.com/
Contact
Categories